What is the share price of Marksans Pharma Ltd (MARKSANS) today?
The share price of MARKSANS as on 25th April 2025 is ₹216.38. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Marksans Pharma Ltd (MARKSANS) share?
The past returns of Marksans Pharma Ltd (MARKSANS) share are- Past 1 week: 0.53%
- Past 1 month: -3.13%
- Past 3 months: -9.59%
- Past 6 months: -15.79%
- Past 1 year: 35.81%
- Past 3 years: 308.90%
- Past 5 years: 1008.59%
What are the peers or stocks similar to Marksans Pharma Ltd (MARKSANS)?
The peers or stocks similar to Marksans Pharma Ltd (MARKSANS) include:What is the dividend yield % of Marksans Pharma Ltd (MARKSANS) share?
The current dividend yield of Marksans Pharma Ltd (MARKSANS) is 0.26.What is the market cap of Marksans Pharma Ltd (MARKSANS) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Marksans Pharma Ltd (MARKSANS) is ₹10348.90 Cr as of 25th April 2025.What is the 52 week high and low of Marksans Pharma Ltd (MARKSANS) share?
The 52-week high of Marksans Pharma Ltd (MARKSANS) is ₹358.70 and the 52-week low is ₹130.What is the PE and PB ratio of Marksans Pharma Ltd (MARKSANS) stock?
The P/E (price-to-earnings) ratio of Marksans Pharma Ltd (MARKSANS) is 32.99. The P/B (price-to-book) ratio is 4.96.Which sector does Marksans Pharma Ltd (MARKSANS) belong to?
Marksans Pharma Ltd (MARKSANS) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Marksans Pharma Ltd (MARKSANS) shares?
You can directly buy Marksans Pharma Ltd (MARKSANS) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Marksans Pharma Ltd
MARKSANS Share Price
216.385.25% (-11.99)
MARKSANS Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
MARKSANS Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 28.10 | 4.96 | 0.26% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 50.69 | 6.47 | 0.52% |
MARKSANS Analyst Ratings & Forecast
Detailed Forecast 100%
Analysts have suggested that investors can buy this stock
from 3 analysts
Price Upside
Earnings Growth
Rev. Growth
MARKSANS Company Profile
Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.
Investor Presentation
View olderMARKSANS Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
45.20
1Y Return
21.41%
Buy Reco %
88.24
CIPLA
PE Ratio
30.41
1Y Return
10.98%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
67.94
1Y Return
23.77%
Buy Reco %
68.00
MANKIND
PE Ratio
56.06
1Y Return
8.38%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.91
1Y Return
0.87%
Buy Reco %
46.67
MARKSANS Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
MARKSANS Stock Summary · November 2024
The company is poised for significant growth, driven by a robust 20.8% year-on-year revenue increase, particularly in the US market, while also anticipating a recovery in the UK. Despite facing challenges with elevated inventory levels due to new product launches, management remains optimistic about future sales, supported by a strong order book and strategic expansions in key regions like Australia and New Zealand. Operational efficiencies are improving, with the Teva facility contributing positively to profits, even as freight costs pose potential risks. The focus on R&D and market dynamics underscores a commitment to innovation and competitive positioning, aiming for a revenue target of INR 3,000 crores within the next two years.
Key Points on Marksans Stock
MARKSANS Stock Growth Drivers
8Strong Revenue Growth
The company reported a robust performance with a 20.8% year-on-year revenue growth in Q2 FY25,
Record EBITDA and Margin Expansion
The company achieved an all-time high quarterly EBITDA of INR 135.7 crores in Q2 FY25,
MARKSANS Stock Challenges
5Operational Challenges Due to Capacity Constraints
The company is currently operating at only 40% to 45% capacity at its Teva facility.
Impact of Seasonal Trends on UK Market Performance
The UK market is experiencing a softer quarter due to seasonal trends, which raises concerns
MARKSANS Forecasts
Price
Revenue
Earnings
MARKSANS Share Price Forecast
2024
Current
₹228.37
Baseline
Forecast for Apr 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹228.37
Baseline
Forecast for Apr 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
MARKSANS Company Revenue Forecast
2024
Current
₹2.23
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2024
Current
₹2.23
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
MARKSANS Stock EPS (Earnings Per Share) Forecast
2024
Current
₹6.92
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2024
Current
₹6.92
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
MARKSANS
Income
Balance Sheet
Cash Flow
Annual Normal View
MARKSANS Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 902.20 | 774.18 | 921.16 | 1,004.69 | 1,134.54 | 1,382.87 | 1,532.69 | 1,911.45 | 2,227.83 | 2,544.79 | ||||||||||
Raw Materials | 504.85 | 506.68 | 502.58 | 517.91 | 514.88 | 731.33 | 703.92 | 927.75 | 1,111.98 | 1,961.87 | ||||||||||
| Power & Fuel Cost | 12.58 | 12.97 | 11.55 | 13.99 | 14.00 | 16.42 | 18.59 | 24.50 | 36.94 | |||||||||||
| Employee Cost | 122.42 | 149.70 | 147.75 | 159.07 | 168.42 | 197.32 | 220.30 | 239.37 | 293.64 | |||||||||||
| Selling & Administrative Expenses | 65.78 | 65.18 | 88.83 | 109.58 | 120.38 | 154.55 | 148.41 | 227.00 | 236.41 | |||||||||||
| Operating & Other expenses | 51.43 | -12.12 | 83.60 | 67.38 | 124.28 | -63.05 | 140.74 | 94.20 | 39.86 | |||||||||||
EBITDA | 145.14 | 51.77 | 86.85 | 136.76 | 192.58 | 346.30 | 300.73 | 398.63 | 509.00 | 582.92 | ||||||||||
| Depreciation/Amortization | 28.13 | 30.09 | 26.84 | 22.80 | 26.66 | 36.15 | 44.78 | 51.85 | 74.27 | 81.70 | ||||||||||
| PBIT | 117.01 | 21.68 | 60.01 | 113.96 | 165.92 | 310.15 | 255.95 | 346.78 | 434.73 | 501.22 | ||||||||||
| Interest & Other Items | 10.16 | 6.78 | 10.22 | 9.66 | 8.75 | 7.99 | 8.45 | 9.13 | 11.20 | 13.06 | ||||||||||
| PBT | 106.85 | 14.90 | 49.79 | 104.30 | 157.17 | 302.16 | 247.50 | 337.65 | 423.53 | 488.16 | ||||||||||
| Taxes & Other Items | 28.33 | 6.06 | 16.86 | 27.84 | 36.42 | 66.22 | 62.95 | 71.34 | 109.83 | 119.82 | ||||||||||
| Net Income | 78.52 | 8.84 | 32.93 | 76.46 | 120.75 | 235.94 | 184.55 | 266.31 | 313.70 | 368.34 | ||||||||||
| EPS | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 6.18 | 6.92 | 8.13 | ||||||||||
| DPS | 0.41 | 0.05 | 0.05 | 0.05 | 0.10 | 0.25 | 0.25 | 0.50 | 0.60 | 0.60 | ||||||||||
| Payout ratio | 0.21 | 0.23 | 0.06 | 0.03 | 0.03 | 0.04 | 0.06 | 0.08 | 0.09 | 0.07 |
MARKSANS Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2025
Investor Presentation
Feb 11PDF
Nov 12PDF
MARKSANS Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Marksans Pharma Ltd | 32.99 | 4.96 | 0.26% |
| Sun Pharmaceutical Industries Ltd | 45.20 | 6.45 | 0.75% |
| Cipla Ltd | 30.41 | 4.68 | 0.84% |
| Torrent Pharmaceuticals Ltd | 67.94 | 16.41 | 0.84% |
MARKSANS Stock Price Comparison
Compare MARKSANS with any stock or ETFCompare MARKSANS with any stock or ETF
MARKSANS
MARKSANS Shareholdings
MARKSANS Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
MARKSANS Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
MARKSANS Shareholding Pattern
MARKSANS Shareholding History
Foreign Institutions
Mutual Funds Invested in MARKSANS
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Marksans Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5781% | Percentage of the fund’s portfolio invested in the stock 2.92% | Change in the portfolio weight of the stock over the last 3 months -0.39% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/44 (-4) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5465% | Percentage of the fund’s portfolio invested in the stock 1.39% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 60/96 (-6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4430% | Percentage of the fund’s portfolio invested in the stock 2.13% | Change in the portfolio weight of the stock over the last 3 months 0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/44 (+1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing MARKSANS stock
Looks like this stock is not in any smallcase yet.
MARKSANS Events
MARKSANS Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
MARKSANS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.28%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.80 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
MARKSANS Upcoming Dividends
No upcoming dividends are available
MARKSANS Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹0.60
Dividend/Share
₹0.60
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateJun 7, 2023
Final
Final | Div/Share: ₹0.50
Dividend/Share
₹0.50
Ex DateEx Date
Jun 7, 2023
Cash Dividend
Ex DateEx DateAug 19, 2022
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Aug 19, 2022
Cash Dividend
Ex DateEx DateSep 15, 2021
Final
Final | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Sep 15, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2020
MARKSANS Stock News & Opinions
Articles & Videos
Corporate
Marksans Pharma's Goa facility receives Australian TGA approval
Marksans Pharma announced that its manufacturing facility located at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa has been approved by Australian TGA for manufacture of pharmaceutical formulations in Solid Dosage Forms of Tablets and hard Capsules for Australian markets. The products will be manufactured at the above facility in Goa India and marketed & distributed in Australian markets through the Company's subsidiary Nova Pharmaceuticals Australasia. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Marksans Pharma rises after receiving regulatory nod for supplying pharma products to Australia
The pharmaceutical formulations include solid dosage forms of tablets and hard capsules. The products will be manufactured at the aforementioned facility located at Verna Industrial Estate, Verna, Goa, and marketed & distributed in Australian markets through the company's subsidiary Nova Pharmaceuticals Australasia. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Relonchem receives UK MHRA marketing authorization for Baclofen 10 mg Tablets
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Baclofen 10 mg Tablets from UK MHRA.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Marksans Pharma gains after arm gets nod for Baclofen tablets from UK MHRA
Baclofen Tablets are used to help relax specific muscles in the body, providing relief from spasms, cramping, and muscle tightness caused by conditions such as multiple sclerosis and certain spinal injuries. While Baclofen does not cure these conditions, it may enhance the effectiveness of other treatments, including physical therapy, in improving patients' overall condition. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Marksans Pharma arm receives marketing authorization for Ibuprofen and Paracetamol
The said medicine is used for the temporary relief of mild to moderate pain such as migraine, headache, backache, period pain, dental pain, rheumatic and muscular pain, cold and flu symptoms, sore throat, and fever. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. Shares of Marksans Pharma shed 0.29% to Rs 225 on the BSE.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Relonchem receives marketing authorization for Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Ibuprofen and Paracetamol 200 mg/500 mg Film-coated Tablets (Bell's Healthcare Dual Action Pain Relief 200 mg/500 mg Film-coated Tablets). Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Marksans Pharma consolidated net profit rises 25.61% in the December 2024 quarter
Net profit of Marksans Pharma rose 25.61% to Rs 104.56 crore in the quarter ended December 2024 as against Rs 83.24 crore during the previous quarter ended December 2023. Sales rose 16.33% to Rs 681.85 crore in the quarter ended December 2024 as against Rs 586.13 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales681.85586.13 16 OPM %20.3522.69 - PBDT163.95134.66 22 PBT143.26112.66 27 NP104.5683.24 26 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Marksans Pharma to table results
Marksans Pharma will hold a meeting of the Board of Directors of the Company on 11 February 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Spotlight
Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA
The said drugs are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from hay fever and other allergies. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The company reported 15.8% increase in consolidated net profit to Rs 96.72 crore on 20.83% rise in revenue from operations to Rs 641.92 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Marksans Pharma receives USFDA approval for Loratadine Tablets
Marksans Pharma announced the final approval of the Company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg from USFDA. They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from hay fever and other allergies.Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 17.27%, vs industry avg of 9.04%
Over the last 5 years, market share increased from 0.46% to 0.58%
Over the last 5 years, net income has grown at a yearly rate of 32.62%, vs industry avg of 15.28%